Tag: WaveWriter

Boston’s WaveWriter SCS systems gain expanded non-surgical back pain indication from...

Boston Scientific Corporation announced today that the US Food and Drug Administration (FDA) has approved an expanded indication of the company’s WaveWriter spinal cord...

Boston Scientific announces positive WaveWriter SCS findings from SOLIS trial

Boston Scientific Corporation has announced positive one-year results from the SOLIS randomised controlled trial, demonstrating sustained pain relief using its WaveWriter Alpha spinal cord...

Boston Scientific to present late-breaking data at NANS 2024

Boston Scientific Corporation has announced its clinical data that will be featured at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January,...

Boston receives expanded US FDA approval of SCS therapy for painful...

Boston Scientific has announced that the US Food and Drug Administration (FDA) has approved an expanded indication of the WaveWriter Alpha spinal cord stimulator...

Boston Scientific announces three-month data from SOLIS trial at NANS

Combination spinal cord stimulation (SCS) therapy with Boston Scientific’s WaveWriter system has demonstrated superior outcomes to conventional medical management (CMM) in chronic pain patients...

Multiple-modality spinal cord stimulation demonstrates sustained improvement in chronic pain outcomes

A spinal cord stimulation (SCS) system capable of simultaneously delivering multiple treatment modalities has produced a sustained improvement in outcomes in a randomised controlled...